RxDoctor Payments Data

Renee Schwertfeger

Family · Morgantown, WVNPI 1417031378

Payments from drug & device makers

$3,292in general payments, 2019–2025

Across 187 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$736
  • Lilly USA, LLC$381
  • Amgen$334
  • Medtronic$304
  • Xeris Pharmaceuticals, Inc.$250
  • Sanofi-aventis U.S. LLC$185
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$1755%
  • Food & beverage$3,11795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,292 in reported general payments places this provider in the 85th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$26,002
Medicare patients
148
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide214$279,477
OzempicSemaglutide196$251,443
MounjaroTirzepatide166$216,089
JardianceEmpagliflozin112$177,190
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/741$61,240
Humulin R U-500 KwikpenInsulin Regular, Human30$52,460
Tresiba Flextouch U-200Insulin Degludec29$49,178
Tresiba Flextouch U-100Insulin Degludec60$46,824
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog48$44,261
Novolog FlexpenInsulin Aspart90$24,468
Fiasp FlextouchInsulin Aspart (Niacinamide)27$23,086
Lantus SolostarInsulin Glargine,hum.Rec.Anlog111$21,762
JanuviaSitagliptin Phosphate23$15,066
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$15,036
BaqsimiGlucagon27$13,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog$381$517,688430 claims
Novo NordiskOzempic, Novolog$736$258,574214 claims
Boehringer IngelheimJardiance$91$177,190112 claims
Sanofi-aventis U.S. LLCLantus$185$2,31011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,507 family providers in West Virginia.

Other family in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →